Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

摘要: Tumour-inhibitory effects of a new antagonist growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 Copenhagen rats implanted with Dunning R-3327 AT-1 prostatic adenocarcinoma. After 6 weeks therapy, the tumour volume cancers treated 40 microg day(-1) MZ-4-71 was significantly decreased to 37 +/- 13 mm3 (P < 0.01) compared controls that measured 194 35 mm3. A similar inhibition obtained cancers, which treatment for 4 diminished 119 397 115 control animals. Therapy also weights tumours increased doubling time. Serum levels GH IGF-I animals GH-RH antagonist. In tissue, IGF-II reduced non-detectable values after therapy MZ-4-71. The inhibited 3 100 i.p. as shown by reduction weight (both P-values 0.05). Specific high-affinity binding sites found on membranes DU-145, tumours. Our results indicate suppresses PC-3, through diminution release resulting decrease secretion hepatic IGF-I, or mechanisms involving lowering possibly an production. antagonists could be considered further development cancer, especially relapse.